ibrutinib
janssen,abbvie
['ibru', 'lymsm', 'cll']
10-yr cll12 follow-up results #17icml
- 363 pts with asympt cll at increased risk randomized to placebo vs ibrutinib
- ibr arm with improved efs/pfs/ttnt
- no diff in os!
- much more cardiotox in ibr arm
impressive study in the btk era that supports watch &amp; wait. #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈